Ncardia innovative hiPSC-based products and services for drug discovery & development

We’re shaping the future of drug discovery & development

Ncardia is a stem cell drug discovery & development company operating worldwide with facilities and offices in Belgium, the Netherlands, Germany and the USA. The company has been established from the merger of Pluriomics and Axiogenesis. Ncardia is built on the belief and trust that stem technology will help to get better medicines to patients faster. The goal of the company is to be the supportive and trusted partner for scientists operating in the hiPSC drug discovery and development space including cardiovascular and neural safety and efficacy studies.

The cardiac products encompass hiPSC-derived cardiomyocytes and a broad neural cell portfolio includes CNS.4U®, Peri.4U® peripheral neurons and Astro.4U® astrocytes. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening along with cardiac safety assessment.

Our history

Ncardia was formed in August 2017 following the merger of Pluriomics and Axiogenesis.

Axiogenesis AG was founded in 2001 as a spin-off of the University of Cologne by Dr. Heribert Bohlen, Prof. Dr. Jürgen Hescheler, and Prof. Dr. Bernd Fleischmann. Pluriomics was founded in 2011 by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.

At the moment of the merger both companies were leading providers in human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug discovery. The combination of the companies brought the best of both organizations together – the people, products, services, industry knowledge and expertise to develop and generate more innovative stem cell based products and services to serve our customers at an even higher level than before.

Board of Directors

The Board of Directors of Ncardia consists of:

  • Herman Spolders (Chairman of the Board, Herman Spolders BVBA)
  • Stefan Braam (CEO, Ncardia)
  • Alain Parthoens (AQ Invest BVBA)
  • Jean Paul Prieels (SFPI-FPIM)
  • Gerty Holla (Participatiemaatschappij InnovationQuarter B.V.)
  • Philippe Degive (Sparaxis SA)
  • Alex Liu Hua (Sino-German beta Holding Co. Ltd)
  • Michael Vogel
  • Guy Heynen


Ncardia is a privately held Belgium-based company with subsidiaries in the Netherlands, Germany and the USA. The investor base of the company includes both public and private funds including Vesalius Biocapital, SFPI-FPIM, SambrInvest, InnovationQuarter, S.R.I.W, Sino-German beta Holding Co. Ltd and founders.

Management team

Ncardia has attracted a leadership team of international experts in the areas of commercialization, pharma services, finance, stem cell R&D and manufacturing.

The management team consists of: